M. Bigler

Type de document

Co-auteur

K. Zaman

R. Winterhalder

A. Wicki

R. Von Moos

M. Vetter

A. Trojan

T. Ruhstaller

T. Rordorf

C. Rochlitz

D. Rauch

K.J. Na

A. Müller

K. Matter-Walstra

M. Küng

U. Hasler-Strub

R. Cathomas

M. Börner

J. Bernhard

D. Bärtschi

S. Anchisi

Date

Source

Serveur académique Lausannois (1)

Mot-clé

toxicité (1) thérapie (1) sécurité (1) qualité de vie (1) infection (1) maladie (1) procès (1) cancer (1) taux (1) survie (1) Treatment (1) Chemotherapy (1) Costs (1) Control (1) Cancer (1) Methods (1) Febrile neutropenia (1) Paclitaxel (1) Rates (1) Ci (Chinese poetry) (1) Therapeutics (1) Theater (1) Survival (1) Quality of life (1) Patients (1) Neuropathy (1) Adjustable rate mortgages (1) Infection (1) Drama (1) December (1)

Documents écrit par M. Bigler (1) | parle de M. Bigler (0)

SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.

C. Rochlitz et al. (2016)